Cited by 244Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration MechanismsNuclear Receptors and Signaling

The DOI matches its Crossref record; 233 of the 233 references it cites were found in a registry or an index.

Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease

Open access

Allen Reish, Heather E., Standaert, David G.·2015·Journal of Parkinson’s Disease

DOI 10.3233/jpd-140491PMC PMC4405142

Open this paper in CoChat — free account

Abstract

Alpha-synuclein (α-syn) is central to the pathogenesis of Parkinson disease (PD). Gene duplications, triplications and point mutations in SNCA1, the gene encoding α-syn, cause autosomal dominant forms of PD. Aggregated and post-translationally modified forms of α-syn are present in Lewy bodies and Lewy neurites in both sporadic and familial PD, and recent work has emphasized the prion-like ability of aggregated α-syn to produce spreading pathology. Accumulation of abnormal forms of α-syn is a trigger for PD, but recent evidence suggests that much of the downstream neurodegeneration may result from inflammatory responses. Components of both the innate and adaptive immune systems are activated in PD, and influencing interactions between innate and adaptive immune components has been shown to modify the pathological process in animal models of PD. Understanding the relationship between α-syn and subsequent inflammation may reveal novel targets for neuroprotective interventions. In this review, we examine the role of α-syn and modified forms of this protein in the initiation of innate and adaptive immune responses.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3233/jpd-140491

Cites

233 of 233 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
α-Synuclein in Lewy bodies
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Macrophage activation and polarization: nomenclature and experimental guidelines
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., Gordon, S., Hamilton, J. A., Ivashkiv, L. B., Lawrence, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.008 · Cited by 6,337
Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
A Lineage of Myeloid Cells Independent of Myb and Hematopoietic Stem Cells
Schulz, C., Perdiguero, E. G., Chorro, L., Szabo-Rogers, H., Cagnard, N., Kierdorf, K., Prinz, M., Wu, B., Jacobsen, S. E. W., Pollard, J. W., et al. (2012) · Science · doi:10.1126/science.1219179 · Cited by 2,578

Flagged first, then by citations

Show all 233 references

Sorted by citations

The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
Exposure to the functional bacterial amyloid protein curli enhances alpha-synuclein aggregation in aged Fischer 344 rats and Caenorhabditis elegans
Chen, S. G., Stribinskis, V., Rane, M. J., Demuth, D. R., Gozal, E., Roberts, A. M., Jagadapillai, R., Liu, R., Choe, K., Shivakumar, B., et al. (2016) · Scientific Reports · doi:10.1038/srep34477 · Cited by 463
Self-assembling dipeptide antibacterial nanostructures with membrane disrupting activity
Schnaider, L., Brahmachari, S., Schmidt, N. W., Mensa, B., Shaham‐Niv, S., Bychenko, D., Adler‐Abramovich, L., Shimon, L. J. W., Kolusheva, S., DeGrado, W. F., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01447-x · Cited by 411
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic
Tan, A. H., Lim, S. Y., & Lang, A. E. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00681-2 · Cited by 392
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
Lang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 384
Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases
Yan, Z., Gibson, S. A., Buckley, J. A., Qin, H., & Benveniste, E. N. (2018) · Clinical Immunology · doi:10.1016/j.clim.2016.09.014 · Cited by 318
S erum immune markers and disease progression in an incident P arkinson's disease cohort ( ICICLE‐PD )
Williams‐Gray, C. H., Wijeyekoon, R., Yarnall, A. J., Lawson, R. A., Breen, D. P., Evans, J., Cummins, G. A., Duncan, G. W., Khoo, T. K., Burn, D. J., et al. (2016) · Movement Disorders · doi:10.1002/mds.26563 · Cited by 310
Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease
Church, F. (2021) · Biomolecules · doi:10.3390/biom11040612 · Cited by 325
Microglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285
Prying into the Prion Hypothesis for Parkinson's Disease
Brundin, P., & Melki, R. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.1788-16.2017 · Cited by 293
Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration
Qin, H., Buckley, J. A., Li, X., Liu, Y., Fox, T. H., Meares, G. P., Yu, H., Yan, Z., Harms, A. S., Li, Y., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4658-15.2016 · Cited by 285
Self-citation
The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders
Pawelec, P., Ziemka‐Nałęcz, M., Sypecka, J., & Zalewska, T. (2020) · Cells · doi:10.3390/cells9102277 · Cited by 284
CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease
Galiano-Landeira, J., Torra, A., Vila, M., & Bové, J. (2020) · Brain · doi:10.1093/brain/awaa269 · Cited by 267
Fyn kinase regulates misfolded α-synuclein uptake and NLRP3 inflammasome activation in microglia
Panicker, N., Sarkar, S., Harischandra, D. S., Neal, M. P., Kam, T., Jin, H., Saminathan, H., Langley, M. R., Charli, A., Samidurai, M., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182191 · Cited by 257
The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson’s Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline
Borghammer, P. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-202481 · Cited by 259
microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease
Thome, A. D., Harms, A. S., Volpicelli‐Daley, L. A., & Standaert, D. G. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.3900-15.2016 · Cited by 252
Self-citation
Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and neurodegeneration in a model of Parkinson disease
Harms, A. S., Thome, A. D., Yan, Z., Schonhoff, A. M., Williams, G. P., Li, X., Liu, Y., Qin, H., Benveniste, E. N., & Standaert, D. G. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.11.010 · Cited by 236
Self-citation
Alpha-Synuclein in Parkinson’s Disease: From Pathogenetic Dysfunction to Potential Clinical Application
Xu, L., & Pu, J. (2016) · Parkinson s Disease · doi:10.1155/2016/1720621 · Cited by 243
The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson’s Diseases
Zhang, J., Li, X., & Li, J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00381 · Cited by 225
Mercury Involvement in Neuronal Damage and in Neurodegenerative Diseases
Cariccio, V. L., Samà, A., Bramanti, P., & Mazzon, E. (2018) · Biological Trace Element Research · doi:10.1007/s12011-018-1380-4 · Cited by 246
Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease
Houser, M. C., Chang, J., Factor, S. A., Molho, E., Zabetian, C. P., Hill‐Burns, E. M., Payami, H., Hertzberg, V., & Tansey, M. G. (2018) · Movement Disorders · doi:10.1002/mds.27326 · Cited by 204
Role of JAK/STAT in the Neuroinflammation and its Association with Neurological Disorders
Jain, M., Singh, M. K., Shyam, H., Mishra, A., Kumar, S., Kumar, A., & Kushwaha, J. K. (2021) · Annals of Neurosciences · doi:10.1177/09727531211070532 · Cited by 196
α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease
Sorrentino, Z. A., Giasson, B. I., & Chakrabarty, P. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01977-2 · Cited by 179
Immune system responses in Parkinson's disease: Early and dynamic
Tansey, M. G., & Romero‐Ramos, M. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14290 · Cited by 193
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
Oliveira, L. M. A., Gasser, T., Edwards, R. H., Zweckstetter, M., Melki, R., Stefanis, L., Lashuel, H. A., Sulzer, D., Vekrellis, K., Halliday, G. M., et al. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00203-9 · Cited by 174
α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era
Visanji, N. P., Brotchie, J. M., Kalia, L. V., Koprich, J. B., Tandon, A., Watts, J. C., & Lang, A. E. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.09.003 · Cited by 174
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
Volc, D., Poewe, W. H., Kutzelnigg, A., Lührs, P., Thun-Hohenstein, C., Schneeberger, A., Galabova, G., Majbour, N. K., Vaikath, N. N., El‐Agnaf, O. M. A., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30136-8 · Cited by 160
Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease
Lim, C. K., Fernández-Gomez, F. J., Braidy, N., Estrada, C., Costa, C., Costa, S., Bessede, A., Fernandez-Villalba, E., Zinger, A., Herrero, M. T., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.009 · Cited by 159
Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant
Hoenen, C., Gustin, A., Birck, C., Kirchmeyer, M., Beaume, N., Felten, P., Grandbarbe, L., Heuschling, P., & Heurtaux, T. (2016) · PLOS ONE · doi:10.1371/journal.pone.0162717 · Cited by 159
Pathological α-synuclein exacerbates the progression of Parkinson’s disease through microglial activation
Zhang, Q.-S., Heng, Y., Yuan, Y.-H., & Chen, N.-H. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2016.11.002 · Cited by 156
Inflammation in Neurological Disorders: The Thin Boundary Between Brain and Periphery
Cervellati, C., Trentini, A., Pecorelli, A., & Valacchi, G. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8076 · Cited by 140
SARS‐CoV ‐2: At the Crossroad Between Aging and Neurodegeneration
Lippi, A., Domingues, R., Setz, C., Outeiro, T. F., & Kriško, A. (2020) · Movement Disorders · doi:10.1002/mds.28084 · Cited by 143
Single-cell transcriptome and TCR profiling reveal activated and expanded T cell populations in Parkinson’s disease
Wang, P., Yao, L., Luo, M., Zhou, W., Jin, X., Xu, Z., Shi, Y., Li, Y., Xu, C., Cheng, R., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00280-3 · Cited by 129
Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease
Amara, A. W., Wood, K. H., Joop, A., Memon, R. A., Pilkington, J., Tuggle, S. C., Reams, J., Barrett, M. J., Edwards, D. A., WELTMAN, A. L., et al. (2020) · Movement Disorders · doi:10.1002/mds.28009 · Cited by 128
RETRACTED ARTICLE: Neuroinflammation is associated with infiltration of T cells in Lewy body disease and α-synuclein transgenic models
Iba, M., Kim, C., Sallin, M., Kwon, S., Verma, A., Overk, C., Rissman, R. A., Sen, R., Sen, J. M., & Masliah, E. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01888-0 · Cited by 120
Retracted
Updates on immunity and inflammation in Parkinson disease pathology
Joshi, N., & Singh, S. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24185 · Cited by 118
Climate change and neurodegenerative diseases
Bongioanni, P., Carratore, R. D., Corbianco, S., Diana, A., Cavallini, G., Masciandaro, S. M., Dini, M., & Buizza, R. (2021) · Environmental Research · doi:10.1016/j.envres.2021.111511 · Cited by 120
Chronic Mild Gut Inflammation Accelerates Brain Neuropathology and Motor Dysfunction in α-Synuclein Mutant Mice
Kishimoto, Y., Zhu, W. S., Hosoda, W., Sen, J. M., & Mattson, M. P. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08539-5 · Cited by 115
Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases
Forloni, G., Artuso, V., Vitola, P. L., & Balducci, C. (2016) · Movement Disorders · doi:10.1002/mds.26624 · Cited by 116
How can rAAV ‐α‐synuclein and the fibril α‐synuclein models advance our understanding of Parkinson's disease?
Volpicelli‐Daley, L. A., Kirik, D., Stoyka, L. E., Standaert, D. G., & Harms, A. S. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13627 · Cited by 123
Self-citation
Promising drug targets and associated therapeutic interventions in Parkinson’s disease
Rai, S. N., Singh, P., Varshney, R., Chaturvedi, V. K., Vamanu, E., Singh, M. P., & Singh, S. P. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306066 · Cited by 109
The role of Th17 cells in auto-inflammatory neurological disorders
Tahmasebinia, F., & Pourgholaminejad, A. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.07.023 · Cited by 111
Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders
Manne, S., Kondru, N. C., Hepker, M., Jin, H., Anantharam, V., Lewis, M. M., Huang, X., Kanthasamy, A., & Kanthasamy, A. G. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09835-4 · Cited by 101
T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease
Williams, G. P., Marmion, D. J., Schonhoff, A. M., Jurkuvenaite, A., Won, W.-J., Standaert, D. G., Kordower, J. H., & Harms, A. S. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02126-w · Cited by 102
Self-citation
TREM2 deficiency aggravates α‐synuclein–induced neurodegeneration and neuroinflammation in Parkinson's disease models
Guo, Y., Wei, X., Yan, H., Qin, Y., Yan, S., Liu, J., Zhao, Y., Jiang, F., & Lou, H. (2019) · The FASEB Journal · doi:10.1096/fj.201900992r · Cited by 101
Immunotherapy for Parkinson’s disease
Schwab, A. D., Thurston, M. J., Machhi, J., Olson, K. E., Namminga, K. L., Gendelman, H. E., & Mosley, R. L. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104760 · Cited by 101
The Cellular Environment Affects Monomeric α-Synuclein Structure
Stephens, A. D., Zacharopoulou, M., & Schierle, G. S. K. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.11.005 · Cited by 91
Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease
Sela, M., Poley, M., Mora‐Raimundo, P., Kagan, S., Avital, A., Kaduri, M., Chen, G., Adir, O., Rozencweig, A., Weiss, Y., et al. (2023) · Advanced Materials · doi:10.1002/adma.202304654 · Cited by 93
Epigenetic Regulation of Neuroinflammation in Parkinson’s Disease
Rasheed, M., Liang, J., Wang, C., Deng, Y., & Chen, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094956 · Cited by 96
The role of natural killer cells in Parkinson’s disease
Earls, R. H., & Lee, J. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00505-7 · Cited by 94
Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation
George, S., & Brundin, P. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150630 · Cited by 97
Alpha-Synuclein Post-translational Modifications: Implications for Pathogenesis of Lewy Body Disorders
Manzanza, N. D. O., Sedlackova, L., & Kalaria, R. N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.690293 · Cited by 98
Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson’s Disease
Madsen, D. A., Schmidt, S. I., Blaabjerg, M., & Meyer, M. (2021) · Cells · doi:10.3390/cells10020283 · Cited by 85
Inflammasome assembly in neurodegenerative diseases
Singh, J., Habean, M. L., & Panicker, N. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.07.009 · Cited by 83
MicroRNA‐190 alleviates neuronal damage and inhibits neuroinflammation via Nlrp3 in MPTP‐induced Parkinson's disease mouse model
Sun, Q., Wang, S., Chen, J., Cai, H., Huang, W., Zhang, Y., Wang, L., & Xing, Y. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28907 · Cited by 82
Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson’s disease
Thome, A. D., Atassi, F., Wang, J., Faridar, A., Zhao, W., Thonhoff, J. R., Beers, D. R., Lai, E. C., & Appel, S. H. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00188-5 · Cited by 80
Dysbiosis of the gut microbiota and its effect on α-synuclein and prion protein misfolding: consequences for neurodegeneration
Mahbub, N. U., Islam, M. M., Hong, S., & Chung, H. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1348279 · Cited by 90
Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease
Kasen, A., Houck, C., Burmeister, A. R., Sha, Q., Brundin, L., & Brundin, P. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105654 · Cited by 78
Unveiling sex-based differences in Parkinson's disease: a comprehensive meta-analysis of transcriptomic studies
López‐Cerdán, A., Andreu, Z., Hidalgo, M. R., Grillo-Risco, R., Català-Senent, J. F., Soler-Sáez, I., Neva-Alejo, A., Gordillo, F., de la Iglesia-Vayá, M., & Garcia‐García, F. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00477-5 · Cited by 77
Role of Nrf2 in Parkinson’s Disease: Toward New Perspectives
Yang, X.-X., Yang, R., & Zhang, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.919233 · Cited by 79
Identification of potential blood biomarkers for Parkinson’s disease by gene expression and DNA methylation data integration analysis
Wang, C., Chen, L., Yang, Y., Zhang, M., & Wong, G. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0621-5 · Cited by 74
Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress
Carroll, C., & Wyse, R. K. H. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171203 · Cited by 73
Neurotransmission systems in Parkinson’s disease
Moghaddam, H. S., Zare-Shahabadi, A., Rahmani, F., & Rezaei, N. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0068 · Cited by 78
Neuroprotective Effects of Resveratrol in In vivo and In vitro Experimental Models of Parkinson’s Disease: a Systematic Review
dos Santos, M. G., Schimith, L. E., André‐Miral, C., Muccillo-Baisch, A. L., Arbo, B. D., & Hort, M. A. (2022) · Neurotoxicity Research · doi:10.1007/s12640-021-00450-x · Cited by 75
The principal molecular mechanisms behind the activation of Keap1/Nrf2/ARE pathway leading to neuroprotective action in Parkinson's disease
Chakkittukandiyil, A., Sajini, D. V., Karuppaiah, A., & Selvaraj, D. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105325 · Cited by 75
Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?
Armentero, M., Cerri, S., & Blandini, F. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00232 · Cited by 75
Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease
Francardo, V., Geva, M., Bez, F., Denis, Q., Steiner, L., Hayden, M. R., & Cenci, M. A. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00699-9 · Cited by 68
Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease
Thome, A. D., Standaert, D. G., & Harms, A. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140566 · Cited by 68
Self-citation
Role of exosomes in the pathogenesis of inflammation in Parkinson’s disease
Yang, X., Li, K., Huang, H., & Ren, H. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335143 · Cited by 68
IL‐1β/IL‐1R1 signaling induced by intranasal lipopolysaccharide infusion regulates alpha‐Synuclein pathology in the olfactory bulb, substantia nigra and striatum
Niu, H., Wang, Q., Zhao, W., Liu, J., Wang, D., Muhammad, B., Liu, X., Quan, N., Zhang, H., Zhang, F., et al. (2020) · Brain Pathology · doi:10.1111/bpa.12886 · Cited by 62
Astroglial and microglial contributions to iron metabolism disturbance in Parkinson's disease
Song, N., Wang, J., Jiang, H. F., & Xie, J. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.01.008 · Cited by 63
Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects
Tomlinson, J. J., Shutinoski, B., Dong, L. M., Meng, F., Elleithy, D., Lengacher, N. A., Nguyen, A., Cron, G. O., Jiang, Q., Roberson, E. D., et al. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1726-7 · Cited by 66
Opioid system influences gut-brain axis: Dysbiosis and related alterations
Rueda‐Ruzafa, L., Cruz, F., Cardona, D., Hone, A. J., Molina‐Torres, G., Sánchez‐Labraca, N., & Román, P. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104928 · Cited by 65
Inhibition effects of tanshinone on the aggregation of α-synuclein
Ji, K., Zhao, Y., Yu, T., Wang, Z., Gong, H., Yang, X., Liu, Y., & Huang, K. (2015) · Food & Function · doi:10.1039/c5fo00664c · Cited by 62
Breaking Boundaries: Chronic Diseases and the Frontiers of Immune Microenvironments
Li, G., Wan, Y., Jiao, A., Jiang, K., Cui, G., Tang, J., Yu, S., Hu, Z., Zhao, S., Yi, Z., et al. (2025) · Med Research · doi:10.1002/mdr2.70007 · Cited by 63
Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism
Uversky, V. N. (2017) · F1000Research · doi:10.12688/f1000research.10536.1 · Cited by 59
Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection
Labrie, V., & Brundin, P. (2017) · Journal of Innate Immunity · doi:10.1159/000479653 · Cited by 60
Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson’s disease etiology
Coetzee, S. G., Pierce, S. E., Brundin, P., Brundin, L., Hazelett, D. J., & Coetzee, G. A. (2016) · Scientific Reports · doi:10.1038/srep30509 · Cited by 56
Abnormal subpopulations of peripheral blood lymphocytes are involved in Parkinson’s disease
Sun, C., Zhao, Z., Yu, W., Mo, M., Song, C., Si, Y., & Liu, Y. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.10.105 · Cited by 55
Motor neuron loss and neuroinflammation in a model of α-synuclein-induced neurodegeneration
Sorrentino, Z. A., Xia, Y., Funk, C., Riffe, C. J., Rutherford, N. J., Ceballos Diaz, C., Sacino, A. N., Price, N. D., Golde, T. E., Giasson, B. I., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.09.005 · Cited by 54
Evidence for a Pan-Neurodegenerative Disease Response in Huntington's and Parkinson's Disease Expression Profiles
Labadorf, A. T., Choi, S. H., & Myers, R. H. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00430 · Cited by 53
The Challenge of the Pathogenesis of Parkinson's Disease: Is Autoimmunity the Culprit?
Jiang, T., Li, G., Xu, J., Gao, S., & Xu, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02047 · Cited by 53
The spatial landscape of glial pathology and T cell response in Parkinson’s disease substantia nigra
Ma, M., Paryani, F., Jakubiak, K. A., Xia, S., Antoku, S., Kannan, A., Lee, J., Madden, N., Kumar, S. S., Li, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62478-3 · Cited by 61
Highlighting Immune System and Stress in Major Depressive Disorder, Parkinson’s, and Alzheimer’s Diseases, with a Connection with Serotonin
Correia, A. S., Cardoso, A., & Vale, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168525 · Cited by 46
A Perspective on Roles Played by Innate and Adaptive Immunity in the Pathobiology of Neurodegenerative Disorders
Gendelman, H. E., & Mosley, R. L. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9639-4 · Cited by 43
Pesticides and the Microbiome-Gut-Brain Axis: Convergent Pathways in the Pathogenesis of Parkinson’s Disease
Kulcsarova, K., Bang, C., Berg, D., & Schaeffer, E. (2023) · Journal of Parkinson’s Disease · doi:10.3233/jpd-230206 · Cited by 40
Crosstalk between PI3K/AKT/KLF4 signaling and microglia M1/M2 polarization as a novel mechanistic approach towards flibanserin repositioning in parkinson's disease
El-Deeb, N. K., El-Tanbouly, D. M., Khattab, M. A., El-Yamany, M. F., & Mohamed, A. F. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109191 · Cited by 39
Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model
Wang, W., Song, N., Jia, F., Tang, T., Bao, W., Zuo, C., Xie, J., & Jiang, H. F. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.01.006 · Cited by 38
Human NPCs can degrade α–syn fibrils and transfer them preferentially in a cell contact-dependent manner possibly through TNT-like structures
Grudina, C., Kouroupi, G., Nonaka, T., Hasegawa, M., Matsas, R., & Zurzolo, C. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104609 · Cited by 39
Size-Selective Phagocytic Clearance of Fibrillar α-Synuclein through Conformational Activation of Complement Receptor 4
Juul‐Madsen, K., Qvist, P., Bendtsen, K. L., Langkilde, A. E., Vestergaard, B., Howard, K. A., Dehesa-Etxebeste, M., Paludan, S. R., Andersen, G. R., Jensen, P. H., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900494 · Cited by 37
Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies
Fleming, S. M., Davis, A., & Simons, E. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108870 · Cited by 37
Inflammatory Responses to Monomeric and Aggregated α-Synuclein in Peripheral Blood of Parkinson Disease Patients
Piancone, F., Saresella, M., Rosa, F. L., Marventano, I., Meloni, M., Navarro, J., & Clerici, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.639646 · Cited by 39
Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction
Mancini, A., Ghiglieri, V., Parnetti, L., Calabresi, P., & Filippo, M. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.644294 · Cited by 38
The gut–brain axis in early Parkinson’s disease: from prodrome to prevention
Oliver, P. J., Civitelli, L., & Hu, M. T. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13138-5 · Cited by 42
“There is evidence for α-synuclein misfolding and aggregation being promoted by an inflammatory microenvironment that subsequently induces an immune response and further inflammation to create a vicious and disease-pro-moting positive feedback loop [118–120].”
The interplay between parkin and alpha-synuclein; possible implications for the pathogenesis of Parkinson’s disease
Jęśko, H. M., Lenkiewicz, A. M., Wilkaniec, A., & Adamczyk, A. (2019) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2019-026 · Cited by 34
Inflammatory Mechanisms in Parkinson’s Disease: From Pathogenesis to Targeted Therapies
Lee, S. Y. H., Yates, N. J., & Tye, S. J. (2021) · The Neuroscientist · doi:10.1177/1073858421992265 · Cited by 34
Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
Gundersen, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580311 · Cited by 33
Pre-clinical Studies Identifying Molecular Pathways of Neuroinflammation in Parkinson's Disease: A Systematic Review
Fathi, M., Vakili, K. G., Yaghoobpoor, S., Qadirifard, M. S., Kosari, M., Naghsh, N., Taei, A. A., Klegeris, A., Dehghani, M., Bahrami, A., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.855776 · Cited by 35

Authors: Allen Reish, H. E., & Standaert, D. G.
Affiliations: Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Alabama, USA
University of Alabama at Birmingham (US)
ORCID: Standaert, David G.
Venue: Journal of Parkinson’s Disease
Publisher: SAGE Publications
Published: 2015-01-01
Volume: 5
Issue: 1
Pages: 1-19
ISSN: 1877-7171 (ISSN-L)
1877-718X
DOI: 10.3233/jpd-140491
PMC: PMC4405142
OpenAlex: W1480927111
Cited by: 244
References: 233
Citations by year: 2026: 11 · 2025: 20 · 2024: 30 · 2023: 20 · 2022: 26 · 2021: 39 · 2020: 20 · 2019: 19 · 2018: 18 · 2017: 18 · 2016: 16 · 2015: 7
FWCI: 13.71
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Parkinson s Disease (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Institute of Neurological Disorders and Stroke (F31NS076017)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: alpha-synuclein, Parkinson's disease, innate immunity, adaptive immunity, neuroinflammation, Lewy bodies, Lewy neurites, prion-like spreading, post-translational modification, neurodegeneration, neuroprotection
MeSH terms: Humans, Immunity, Innate, Parkinson Disease, alpha-Synuclein, Adaptive Immunity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks